SIETES :: 93212 citas

Resultados de la búsqueda por NOTIFICACIÓN VOLUNTARIA REFINAR BÚSQUEDA

1.

VRBPAC Briefing Document. Pfizer-BioNTech Covid-19 vaccine (bnt162, pf-07302048) Vaccines and Related Biological Products Advisory Committee. Briefing document. Meeting date: 10 December 2020. U.S. Food and Drug Administration 2020:14 de diciembre. [Ref.ID 103835]

2.

López C. El número de fallecidos por la Covid-19 supera ya los 50.000. La Vanguardia 2020:29 de diciembre. [Ref.ID 103834]

3.

Anónimo. COVID-19 vaccines and severe allergic reactions. Centers for Disease Control and Prevention 2020:19 de diciembre. [Ref.ID 103829]

4.

Axelrod T. FDA investigating allergic reactions to Pfizer vaccine reported in multiple states. The Hill 2020:19 de diciembre. [Ref.ID 103828]

5.

Nguyen D-D, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, Trinh Q-D. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol 2020:11 de noviembre. [Ref.ID 103784]

6.

Nguyen LS, Dolladille C, Drici M-D, Fenioux C, Alexandre J, Mira J-P, Moslehi JJ, Roden DM, Funck-Brentano C, Salem J-E. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization pharmacovigilance database. Circulation 2020;142:22 de mayo. [Ref.ID 103660]

7.

Anónimo. In brief: Neuropsychiatric events with montelukast. Med Lett Drugs Ther 2020;62:65. [Ref.ID 103638]

8.

Lafaurie M, Olivier P, Khouri C, Atzenhoffer M, Bihan K, Durrieu G, Montastruc J-L. Myocardial infarction and ischemic stroke with vasoconstrictors used as nasal decongestant for common cold: a French pharmacovigilance survey. Eur J Clin Pharmacol 2020;76:603-4. [Ref.ID 103616]

9.

Anónimo. FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. Risks may include suicidal thoughts or actions. U.S. Food and Drug Administration 2020:4 de marzo. [Ref.ID 103559]

10.

Anónimo. Neurontin, Gralise, Horizant (gabapentin) and Lyrica, Lyrica CR (pregabalin): Drug safety communication - Serious breathing problems. U.S. Food and Drug Administration 2019:19 de diciembre. [Ref.ID 103239]

11.

Marsh S. Suicides linked to acne drug Roaccutane as regulator reopens inquiry. The Guardian 2019:27 de diciembre. [Ref.ID 103237]

12.

Dardonville Q, Salgueiro E, Rousseau V, Chebane L, Faillie JL, Gautier S, Montastruc JL, Carvajal A, Bagheri H. Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol 2019;75:1705-11. [Ref.ID 103213]

13.

Azzouz B, Morel A, Kanagaratman L, Herlem E, Trenque T. Psoriasis after exposure to angiotensin-converting enzyme inhibitors: French pharmacovigilance data and review of the literature. Drug Saf 2019;42:diciembre. [Ref.ID 103209]

14.

Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: A pharmacovigilance study of the FDA adverse event reporting system. International Journal of Medical Sciences 2019;16:julio. [Ref.ID 103207]

15.

Healy D, Mangin D. Clinical judgments, not algorithms, are key to patient safety. BMJ 2019;367:2 de octubre. [Ref.ID 103204]

16.

Anónimo. Hepatitis C medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to rare occurrence of serious liver injury in some patients with advanced liver disease. FDA MedWatch alert 2019:28 de agosto. [Ref.ID 103166]

17.

Sultana J, Moretti U, Addis A, Caduff P, Capuano A, Kant A, Laporte JR, Lindquist M, Raine J, Sartori D, Trifirò G, Tuccori M, Venegoni M, van Puijenbroek E, Leone R. Workshop on the Italian pharmacovigilance system in the international context: critical issues and perspectives. Drug Saf 2019;42:mayo. [Ref.ID 103115]

18.

Anónimo. FDA requires stronger warnings about rare but serious incidents related to certain prescription insomnia medicines. Updated warnings for eszopiclone, zaleplon and zolpidem. U.S. Food and Drug Administration 2019:30 de abril. [Ref.ID 103113]

19.

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]

20.

Abrahami D, Douros A, Yin H, Hu OHY, Faillie J-L, Montastruc F, Platt RW, Bouganim N, Azoulay L. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 2018;363:5 de diciembre. [Ref.ID 102894]